ArticleThe Journal of infectious diseases2017
Prevalence of Genital Human Papillomavirus in Males, United States, 2013-2014.
Article in The Journal of infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis.The Lancet. Global health · 2023Pooled it
- Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review.BMC medicine · 2018Pooled it
- Racial disparities in time to treatment initiation and survival outcomes in patients with vulvar cancer: a national cancer database analysis.International journal of clinical oncology · 2026Observational
- Anal Dysplasia: Epidemiology, Risk Factors, and Progression to Malignancy.Clinics in colon and rectal surgery · 2026Review
- Prevalence of Human Papillomavirus Genotypes in Unvaccinated 16- to 20-Year-Old Men in Quebec, Canada.The Journal of infectious diseases · 2025Article
- The necessity and challenges of human papillomavirus testing for men.Frontiers in cellular and infection microbiology · 2025Review
- Nativity and racial/ethnic differences in HPV infection among U.S. adults, NHANES 2007-2016.Frontiers in public health · 2025Article
- HPV and Penile Cancer: Epidemiology, Risk Factors, and Clinical Insights.Pathogens (Basel, Switzerland) · 2024Review
- Broad-Spectrum Detection of HPV in Male Genital Samples Using Target-Enriched Whole-Genome Sequencing.Viruses · 2023Article
- Article
- Transmission and clearance of human papillomavirus infection in the oral cavity and its role in oropharyngeal carcinoma - A review.Reviews in medical virology · 2023Review
- Trends of genital wart in Korea according to treatment method classification: Big data analysis of health care in 2010-2019.Investigative and clinical urology · 2023Article
- Review of human papillomavirus (HPV) burden and HPV vaccination for gay, bisexual, and other men who have sex with men and transgender women in the United States.Human vaccines & immunotherapeutics · 2022Review
- Factors Related to HPV Vaccination Intention among MSM in China: A Bayesian Network Model.International journal of environmental research and public health · 2022Article
- Human Papillomavirus Vaccine Impact and Effectiveness Through 12 Years After Vaccine Introduction in the United States, 2003 to 2018.Annals of internal medicine · 2022Article
- Factors Influencing Men's Attitudes toward HPV Vaccination in Males Included in the Chinese National Immunization Program.Vaccines · 2022Article
- Willingness to human papillomavirus (HPV) vaccination and influencing factors among male and female university students in China.Journal of medical virology · 2022Article
- HPV Vaccination among Sexual and Gender Minority Youth Living with or at High-Risk for HIV.Vaccines · 2022Article
- Sexual function and sexual quality of life in men with genital warts: a cross-sectional study.Reproductive health · 2022Article
- Effectiveness of Human Papillomavirus (HPV) Vaccination Against Penile HPV Infection in Men Who Have Sex With Men and Transgender Women.The Journal of infectious diseases · 2022Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe report the first nationally representative prevalence data on genital human papillomavirus (HPV) in males in the United States, using findings from the National Health and Nutrition Examination Surveys, 2013-2014.
methodsUsing penile swabs from males aged 14-59 years, we estimated the HPV DNA prevalence and prevalence ratios (PRs) with respect to sexual behaviors and demographic characteristics.
resultsThe prevalence of any HPV was 42.2% (95% confidence interval [CI], 38.3%-46.1%) and of high-risk (HR) HPV was 23.4% (95% CI, 21.3%-25.6%). Prevalence of any HPV was 12.5% in 14-19 year olds and was higher in older age groups, through ages 25-29 years, and then similar through age 59 years. After adjustment for age and race, any HPV prevalence was associated with lifetime number of sex partners (≥15 vs 1-2; PR, 3.27; 95% CI, 2.12-5.02) and past-year number of sex partners (≥2 vs 0; PR, 1.26; 95% CI, 1.09-1.46). Comparisons of consecutively older age groups revealed that the prevalence of quadrivalent HPV vaccine types (4vHPV), types 6, 11, 16, and 18, was significantly higher only between ages 25-29 and 20-24 years (PR, 2.79; 95% CI, 1.31-5.96), whereas the prevalence of other HPV types was significantly higher only between ages 20-24 and 14-19 years (PR, 3.39; 95% CI, 2.49-4.61).
conclusionsOverall, 42.2% of US males aged 14-59 years have detectable genital HPV infections. Differences in the age-specific prevalence of 4vHPV types and non-4vHPV types suggest that the vaccination program has had an impact on the prevalence of HPV types 6, 11, 16, and 18 among males.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.